Immuneering (IMRX) EPS (Basic): 2020-2023
Historic EPS (Basic) for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$0.52.
- Immuneering's EPS (Basic) fell 4.00% to -$0.52 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.89, marking a year-over-year increase of 1.56%. This contributed to the annual value of -$1.88 for FY2023, which is 1.57% up from last year.
- According to the latest figures from Q4 2023, Immuneering's EPS (Basic) is -$0.52, which was down 20.93% from -$0.43 recorded in Q3 2023.
- Over the past 5 years, Immuneering's EPS (Basic) peaked at -$0.05 during Q4 2021, and registered a low of -$1.61 during Q2 2021.
- Its 3-year average for EPS (Basic) is -$0.60, with a median of -$0.49 in 2022.
- Its EPS (Basic) has fluctuated over the past 5 years, first spiked by 95.76% in 2021, then plummeted by 900.00% in 2022.
- Immuneering's EPS (Basic) (Quarterly) stood at -$1.18 in 2020, then skyrocketed by 95.76% to -$0.05 in 2021, then plummeted by 900.00% to -$0.50 in 2022, then declined by 4.00% to -$0.52 in 2023.
- Its EPS (Basic) was -$0.52 in Q4 2023, compared to -$0.43 in Q3 2023 and -$0.43 in Q2 2023.